U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Technical Specifications for Submitting Clinical Trial Data Sets for Treatment of Noncirrhotic Nonalcoholic Steatohepatitis (NASH)
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

Technical Specifications for Submitting Clinical Trial Data Sets for Treatment of Noncirrhotic Nonalcoholic Steatohepatitis (NASH) Guidance for Industry Technical Specifications Document December 2024

Download the Final Guidance Document
Final Level 2 Guidance
Docket Number:
FDA-2018-D-1216
Issued by:
Guidance Issuing Office
Center for Drug Evaluation and Research

This document provides detailed information and specifications for the content of the tabulated domains and analysis data sets submitted to FDA as part of the sponsor’s application for drugs intended to treat noncirrhotic nonalcoholic steatohepatitis (NASH). Revised nomenclature for NASH was introduced in 2023. The new nomenclature for NASH is metabolic dysfunction-associated steatohepatitis (MASH) with no change in histopathological criteria. FDA considers the term NASH interchangeable with MASH and has maintained the former nomenclature for NASH in this guidance pending universal acceptance of the new nomenclature.

This guidance does not provide recommendations for clinical development of drugs intended for the treatment of NASH, or assessment of potential drug-induced liver injury.

Submit Comments

Submit Comments Online

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2018-D-1216.

Back to Top